JP2011505867A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505867A5
JP2011505867A5 JP2010538953A JP2010538953A JP2011505867A5 JP 2011505867 A5 JP2011505867 A5 JP 2011505867A5 JP 2010538953 A JP2010538953 A JP 2010538953A JP 2010538953 A JP2010538953 A JP 2010538953A JP 2011505867 A5 JP2011505867 A5 JP 2011505867A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
humanized antibody
hepatitis
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010538953A
Other languages
English (en)
Japanese (ja)
Other versions
JP5763344B2 (ja
JP2011505867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2008/003952 external-priority patent/WO2009081285A2/en
Publication of JP2011505867A publication Critical patent/JP2011505867A/ja
Publication of JP2011505867A5 publication Critical patent/JP2011505867A5/ja
Application granted granted Critical
Publication of JP5763344B2 publication Critical patent/JP5763344B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010538953A 2007-12-17 2008-12-17 C型肝炎ウイルス抗体 Expired - Fee Related JP5763344B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US606607P 2007-12-17 2007-12-17
US61/006,066 2007-12-17
PCT/IB2008/003952 WO2009081285A2 (en) 2007-12-17 2008-12-17 Hepatitis c virus antibodies

Publications (3)

Publication Number Publication Date
JP2011505867A JP2011505867A (ja) 2011-03-03
JP2011505867A5 true JP2011505867A5 (enExample) 2014-05-22
JP5763344B2 JP5763344B2 (ja) 2015-08-12

Family

ID=40801628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538953A Expired - Fee Related JP5763344B2 (ja) 2007-12-17 2008-12-17 C型肝炎ウイルス抗体

Country Status (18)

Country Link
US (1) US9193781B2 (enExample)
EP (1) EP2231704B1 (enExample)
JP (1) JP5763344B2 (enExample)
KR (1) KR20100102163A (enExample)
CN (1) CN101939334B (enExample)
AR (1) AR072039A1 (enExample)
AU (1) AU2008341542B2 (enExample)
BR (1) BRPI0821252A2 (enExample)
CA (1) CA2708740C (enExample)
CL (1) CL2008003784A1 (enExample)
IL (1) IL205795A0 (enExample)
MX (1) MX2010006767A (enExample)
NZ (1) NZ585622A (enExample)
PE (1) PE20091109A1 (enExample)
RU (1) RU2462475C2 (enExample)
TW (1) TW200940090A (enExample)
WO (1) WO2009081285A2 (enExample)
ZA (1) ZA201003509B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591524A (en) 2004-10-07 2012-09-28 Transmedics Inc Method for timing pulsatile flow of normothermic perfusate to the heart in ex-vivo organ care
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US8420380B2 (en) 2008-01-31 2013-04-16 Transmedics, Inc. Systems and methods for ex vivo lung care
US20120027722A1 (en) * 2008-12-17 2012-02-02 Medical Research Council Hepatitis c virus combination therapy
EP2704560B1 (en) 2011-04-14 2022-04-06 Transmedics, Inc. Organ care solution for ex-vivo machine perfusion of donor lungs
EP2705150B1 (en) * 2011-05-02 2020-07-29 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
WO2013033319A2 (en) * 2011-08-30 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University A cluster of neutralizing antibodies to hepatitis c virus
KR20140106668A (ko) * 2011-12-09 2014-09-03 어플라이드 머티어리얼스, 인코포레이티드 가열 튜브를 냉각시키기 위한 열 교환기 및 그 냉각 방법
ITFI20120122A1 (it) * 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
CN102928595A (zh) * 2012-10-12 2013-02-13 武汉康苑生物医药科技有限公司 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
HK1225631A1 (zh) 2013-09-19 2017-09-15 Novavax, Inc. 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
US10076112B2 (en) 2014-06-02 2018-09-18 Transmedic, Inc. Ex vivo organ care system
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
WO2016090498A1 (en) 2014-12-12 2016-06-16 Freed Darren Apparatus and method for organ perfusion
EP3347084B1 (en) 2015-09-09 2020-11-11 Transmedics, Inc. Aortic cannula for ex vivo organ care system
CN105219780B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用
CN105177017B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r4-85及其应用
WO2017162678A1 (en) * 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
CA3025673A1 (en) 2016-05-30 2017-12-07 Tevosol, Inc. Apparatus and method for ex vivo lung ventilation with a varying exterior pressure
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206131A (pt) * 1991-06-10 1995-05-02 Lucky Ltd Hepatite C: diagnóstico e vacinas
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
US20060188511A1 (en) 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
CA2429946A1 (en) * 2000-12-01 2002-07-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
ITRM20020049A1 (it) * 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
CA2601400A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections

Similar Documents

Publication Publication Date Title
RU2462475C2 (ru) Антитела против вируса гепатита с
EP3048115B1 (en) Monoclonal antibodies for ebola and marburg viruses
JP2015503909A5 (enExample)
JP2012504955A5 (enExample)
JP2018535650A5 (enExample)
JP2008542278A5 (enExample)
JP2018514193A5 (enExample)
JP2015534982A5 (enExample)
JP2010528601A5 (enExample)
JP2011527902A5 (enExample)
JP2011528902A5 (enExample)
JP2007097598A5 (enExample)
JP2023528235A5 (enExample)
JP2010518854A5 (enExample)
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
JP2011527899A5 (enExample)
JP2010526076A5 (enExample)
JP2018518940A5 (enExample)
CA3001231C (en) Antibody against hepatitis b surface antigen and use thereof
JP2012504602A5 (enExample)
CN114736291B (zh) 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
JP2009524428A5 (enExample)
Wang et al. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA. 1-BA. 5
JP2024149479A (ja) 黄熱を処置するための方法および組成物
JPWO2022044573A5 (enExample)